<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Select antiretroviral and non-rifamycin-based antituberculosis drug overlapping toxicities and potential adverse drug-drug interactions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Select antiretroviral and non-rifamycin-based antituberculosis drug overlapping toxicities and potential adverse drug-drug interactions</h1>
<div class="graphic"><div class="figure"><div class="ttl">Select antiretroviral and non-rifamycin-based antituberculosis drug overlapping toxicities and potential adverse drug-drug interactions</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Potential overlapping toxicities and drug–drug interactions</td> <td class="subtitle1">Antiretroviral drugs</td> <td class="subtitle1">Non-rifamycin TB drugs</td> </tr> <tr class="divider_bottom"> <td>Arrhythmias, QT interval prolongation</td> <td> <p>Lopinavir/ritonavir, efavirenz</p> Note PR interval prolongation* with atazanavir, lopinavir/ritonavir</td> <td>Fluoroquinolones<sup>¶</sup>, bedaquiline, delamanid, clofazimine</td> </tr> <tr class="divider_bottom"> <td>Hepatic cytochrome P450 enzyme system metabolism</td> <td> <p>Induce CYP P450 metabolism: efavirenz, etravirine, and nevirapine</p> Impede CYP P450 metabolism: protease inhibitors, cobicistat</td> <td>Bedaquiline, delamanid</td> </tr> <tr class="divider_bottom"> <td>Nephrotoxicity</td> <td> <p>Tenofovir,<sup>Δ</sup> atazanavir</p> Isolated creatinine elevation<sup>◊</sup>: cobicistat, dolutegravir</td> <td>Aminoglycosides, capreomycin</td> </tr> <tr class="divider_bottom"> <td>Mental health changes (depression, psychosis, dizziness, etc.)</td> <td>Efavirenz, rilpivirine; dolutegravir, elvitegravir, raltegravir</td> <td>Cycloserine, isoniazid, ethionamide, fluoroquinolones†</td> </tr> <tr class="divider_bottom"> <td>Peripheral neuropathy</td> <td>Stavudine, zidovudine</td> <td>Aminoglycosides, capreomycin, linezolid, isoniazid, ethionamide, cycloserine, fluoroquinolones<sup>¶</sup></td> </tr> <tr class="divider_bottom"> <td>Hepatotoxicity</td> <td> <p>Lactic acidosis with hepatic steatosis higher risk with stavudine, zidovudine; protease inhibitors; nevirapine (higher risk in patients with elevated CD4 cell counts); less common with efavirenz, etravirine and rilpivirine; maraviroc</p> Indirect hyperbilirubinemia<sup>§</sup>: atazanavir</td> <td>Isoniazid, pyrazinamide, ethionamide, p-aminosalicylic acid, clofazimine</td> </tr> <tr class="divider_bottom"> <td>Skin rash</td> <td> <p>Nevirapine (higher risk in patients with elevated CD4 cell counts), efavirenz, etravirine, rilpivirine</p> Any protease inhibitor (especially those containing sulfonamide moiety: eg, darunavir); abacavir (hypersensitive reaction a risk in patient who are HLA-B5701 positive); raltegravir</td> <td> <p>All TB drugs</p> <p>Note skin pigmentation with clofazimine use</p> Thioacetazone should be avoided in people with HIV, because of an elevated risk of a severe adverse skin reaction</td> </tr> <tr class="divider_bottom"> <td>Dysglycemia</td> <td>Lopinavir/ritonavir, ritonavir, stavudine, zidovudine</td> <td>Ethionamide, p-aminosalicylic acid, fluoroquinolones, linezolid</td> </tr> <tr class="divider_bottom"> <td>Myelosuppression/cytopenias</td> <td>Zidovudine</td> <td>Linezolid</td> </tr> <tr> <td>Lactic acidosis</td> <td>Stavudine, zidovudine</td> <td>Linezolid</td> </tr> </tbody></table></div><div class="graphic_lgnd">Saquinavir, indinavir, fosamprenavir, tipranavir, and didanosine are older antiretroviral drugs that are rarely used in the United States. They do have many of the adverse interactions listed above with select TB drugs, and clinicians considering the use of these agents should therefore consult with an expert.</div><div class="graphic_footnotes">TB: tuberculosis.<br/>	

	* Use with caution in patients with underlying cardiac dysrhythmia.<br/>	

	¶ Fluoroquinolones include ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.<br/>	

	Δ Tenofovir alafenamide is a prodrug of tenofovir and U.S. Food and Drug Administration approved in 2015. It is associated with decreased incidence of osteoporosis and nephrotoxicity compared with tenofovir disoproxil fumarate through achieving higher intracellular drug concentrations with a lower dose administered.<br/>
<span class="lozenge">◊</span> Increases in serum creatinine via decrease in renal tubular creatinine excretion are commonly seen with cobicistat and dolutegravir usage. This is not a toxicity.<br/>	

	§ Indirect hyperbilirubinemia is expected with atazanavir and indinavir. This is not a toxicity.</div><div class="graphic_reference">Reprinted with permission of the American Thoracic Society. Copyright © 2019 American Thoracic Society. From: Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med 2019; 200:e93. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id="graphicVersion">Graphic 53563 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
